Verge Genomics

Technology has transformed every aspect of our lives. Yet, it still takes 12 years to develop a single drug because 90% of drugs fail in clinical trials, leaving hundreds of millions of patients without effective treatments. Accelerating the pace of bringing new, effective medicines to patients is one of the greatest opportunities for humanity.

Our mission is to develop better drugs, faster using artificial intelligence (AI) and human data. We have created a proprietary, all-in-human AI drug discovery engine, CONVERGE, which houses one of the field's largest and most comprehensive databases of multi-modal patient data sourced directly from human tissue. We use machine learning to map the complex causes of disease, discover new targets with a greater probability of success, and de-risk drug development.

We have delivered 2 new drugs from CONVERGE to clinical trials, discovered 282 new targets, and signed 2 commercial partnerships with Eli Lilly and AstraZeneca totaling $1.6B. We are a team of engineers, neuroscientists, and drug developers united around an audacious vision: to build the Genentech of the digital age.